From: Cervical cancer heterogeneity: a constant battle against viruses and drugs
Trial identifier | Brief title | Estimated Enrollment | Criteria | Arms and Interventions | Primary outcome measures [Time Frame] | Estimated Study Completion Date |
---|---|---|---|---|---|---|
NCT02422563 | Neoadjuvant chemotherapy followed by radical hysterectomy (op) versus primary chemo-radiation in cervical cancer FIGO stage IB2 and IIB | 534 | IB2, IIB | Arm I: NACT + Radical hysterectomy Arm II: CCRT | DFS [5 years] | October 2025 |
NCT02629718 | Neoadjuvant chemotherapy + surgery versus surgery in FIGO IB2 and IIA2 cervical cancer | 700 | IB2, IIA2 | Arm I: NACT + Radical hysterectomy Arm II: Radical hysterectomy | DFS [2 years] | December 2022 |
NCT01101451 | Radiation therapy with or without chemotherapy in patients with stage I-IIA cervical cancer who previously underwent surgery | 360 | I-IIA | Arm I: EBRT/IMRT Arm II: Cisplatin + EBRT/IMRT | RFS [11 years] | December 2021 |
NCT04723875 | Postoperative adjuvant chemotherapy in early-stage cervical cancer that not meet criteria of adjuvant therapeutic according to NCCN guideline | 306 | IB1, IB2, IIA1 | Arm I: Chemotherapy Arm II: No intervention | DFS [3Â years] | January 2026 |
NCT05277688 | Adjuvant concurrent chemoradiotherapy versus radiotherapy in early-stage cervical cancer patients | 340 | IA2-IIB | Arm I: Cisplatin + IMRT Arm II: IMRT | RFS [5 years] | December 2027 |
NCT00980954 | Chemotherapy and pelvic radiation therapy with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hysterectomy | 238 | IA2-IIA | Arm I: CCRT Arm II: CCRT + Chemotherapy | DFS [4 years] | August 2026 |
NCT04989647 | Intermediate risk cervical cancer: radical surgery  ± adjuvant radiotherapy | 514 | IB1-IIA | Arm I: Surgery only Arm II: Surgery + Radiation Therapy | DFS [3 years] | December 2032 |
NCT03830866 | Study of durvalumab with chemoradiotherapy for women with locally advanced cervical cancer | 770 | IB2 with positive nodes to IVA (FIGO2009) | Arm I: Durvalumab + CCRT Arm II: Placebo + CCRT | PFS [4.5 years] | June 2023 |
NCT04138992 | A study on the efficacy and safety of bevacizumab in untreated patients with locally advanced cervical cancer | 150 | I-IIIC | Arm I: Bevacizumab + NACT + CCRT Arm II: Bevacizumab + CCRT Arm III: CCRT | DFS [3 years] | May 2022 |
NCT02853604 | Study of ADXS11-001 in subjects with high risk locally advanced cervical cancer | 450 | Locally advanced | Arm I: Placebo Arm II: ADXS11-001 | DFS [5Â years] | October 2024 |
NCT01566240 | Induction chemotherapy plus chemoradiation as first line treatment for locally advanced cervical cancer | 500 | IB1- IVA with positive lymph nodes | Arm I: CCRT Arm II: Chemotherapy + CCRT | OS [5 years] | May 2026 |
NCT03534713 | Induction chemotherapy followed by standard therapy in cervical cancer with aortic lymph node spread | 310 | IB1-IVA with positive para-aortic lymph nodes | Arm I: NACT + CCRT Arm II: CCRT | OS [3 years] | December2024 |
NCT03468010 | A trial comparing adjuvant chemotherapy with observation after concurrent chemoradiotherapy of cervical cancer (with pelvic or para-aortic node involvement) | 432 | IB1-IVA with positive lymph nodes | Arm I: CCRT Arm II: Chemotherapy + CCRT | PFS [3 years] | March 2025 |
NCT05173272 | Induction chemotherapy followed by concurrent chemoradiation in advanced cervical cancer | 286 | IB3-IIIB | Arm I; NACT + CCRT Arm II: CCRT | PFS [3 years] | February 2028 |
NCT04974346 | Para-aortic prophylactic irradiation for locally advanced cervical cancer | 450 | IB2-IV with positive pelvic lymph nodes and negative common iliac and paraaortic lymph nodes (FIGO 2009) | Arm I: Para-aortic Prophylactic Irradiation + CCRT Arm II: CCRT | PFS [3 years] | August 2030 |
NCT05235516 | A study of AK104/placebo combined with chemoradiotherapy for the treatment of locally advanced cervical cancer | 636 | IIIA-IVA | Arm I: AK104 + CCRT Arm II: Placebo + CCRT | PFS [4.5 years] | May 2029 |
NCT01414608 | Cisplatin and radiation therapy with or without carboplatin and paclitaxel in patients with locally advanced cervical cancer | 900 | IB1 with node positive, IB2, IIA, IIB, IIIB, or IVA (FIGO 2008) | Arm I: CCRT Arm II: CCRT + Chemotherapy | OS [5 years] | July 2022 |
NCT05189028 | Study of neoadjuvant chemotherapy versus definite concurrent chemoradiotherapy for locally advanced bulk cervical cancer | 290 | IB3, IIA2, IIB-IVA | Arm I: NACT Arm II: CCRT | OS [2Â years] | June 2025 |
NCT04221945 | Study of chemoradiotherapy with or without pembrolizumab (MK-3475) for the treatment of locally advanced cervical cancer | 980 | IB2-IVA with positive nodes (FIGO 2014) | Arm I: CCRT + Pembrolizumab Arm II: CCRT + Placebo | PFS [38 months] OS [46 months] | December 2024 |
NCT03635567 | Efficacy and safety study of first-line treatment with pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy in women with persistent, recurrent, or metastatic cervical cancer | 600 | Persistent, recurrent, metastatic | Arm I: Pembrolizumab + Chemotherapy ± Bevacizumab Arm II: Placebo + Chemotherapy ± Bevacizumab | PFS [2 years] OS [2 years] | November 2022 |
NCT04906993 | Camrelizumab combined with famitinib malate for treatment of recurrent/metastatic cervical cancer | 440 | Recurrent, metastatic | Arm I: Camrelizumab + Famitinib malate + Chemotherapy Arm II: Chemotherapy | PFS [2 years] OS [2 years] | May 2023 |
NCT04733820 | Clinical efficacy of adjuvant chemotherapy in patients with locally advanced cervical cancer who did not meet the NCCN guidelines for adjuvant treatment after NACT combined with surgery | 340 | IB3-IIB | Arm I: Chemotherapy Arm II: No intervention | DFS [5Â years] | February 2028 |
NCT05367206 | Neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation for stage IIIC cervical cancer patients: a randomized phase III trial | 280 | IIIC | Arm I: albumin-bound paclitaxel and carboplatin + CCRT Arm II: CCRT | PFS [3 years] | March 2027 |
NCT03556839 | Platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab in metastatic carcinoma of the cervix | 404 | IVB, persistent, recurrent | Arm I: Chemotherapy + Bevacizumab Arm II: Atezolizumab + Chemotherapy + Bevacizumab | PFS [48 months] OS [48 months] | December 2023 |
NCT05179239 | A study of SHR-1701 plus platinum-containing chemotherapy with or without BP102 (bevacizumab) as first-line treatment in cervical cancer | 572 | Persistent, recurrent, metastatic | Arm I: SHR-1701 + Chemotherapy + Bevacizumab Arm II: SHR-1701 + Chemotherapy ± Bevacizumab Arm III: Placebo + Chemotherapy ± Bevacizumab | AEs [21 days] PFS [10 months] OS [26 months] | May 2025 |
NCT04982237 | A study of AK104 plus platinum-containing chemotherapy ± bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer | 440 | Persistent, recurrent, metastatic | Arm I: AK104 + Chemotherapy ± Bevacizumab Arm II: Placebo + Chemotherapy ± Bevacizumab | PFS [2 years] OS [2 years] | December 2025 |
NCT03912415 | Efficacy and safety of BCD-100 (anti-PD-1) in combination with platinum-based chemotherapy with and without bevacizumab as first-line treatment of subjects with advanced cervical cancer | 316 | Recurrent or IVB | Arm I: BCD-100 + Chemotherapy ± Bevacizumab Arm II: Placebo + Chemotherapy ± Bevacizumab | OS [3 years] | December 2024 |
NCT03257267 | Study of cemiplimab in adults with cervical cancer | 608 | Persistent, recurrent, metastatic | Arm I: Cemiplimab Arm II: Investigator's choice Chemotherapy | OS [40Â months] | July 2023 |
NCT04300647 | A study of tiragolumab plus atezolizumab and atezolizumab monotherapy in participants with metastatic and/or recurrent PD-L1-positive cervical cancer | 172 | Metastatic, recurrent | Arm I: Tiragolumab + Atezolizumab Arm II: Atezolizumab | ORR [3 years] | July 2023 |
NCT04697628 | Tisotumab vedotin vs chemotherapy in recurrent or metastatic cervical cancer | 482 | Recurrent, metastatic | Arm I: Tisotumab vedotin Arm II: Investigator's choice Chemotherapy | OS [2Â years] | May 2024 |
NCT04864782 | QL1604 plus chemotherapy versus chemotherapy in subjects with stage IVb, recurrent, or metastatic cervical cancer | 458 | Recurrent or IVB | Arm I: QL 1604 + Investigator’s choice Chemotherapy Arm II: Placebo + Investigator’s choice Chemotherapy | AEs [90 days] ORR [6 months] PFS [2 years] | July 2022 |